Entresto Facing Pressure From Diabetes Drugs

With diabetes therapeutics adding cardiovascular risk reduction claims, Novartis's heart failure drug Entresto could face pressure from new fronts – just as sales start to take off.

Pressure
SGLT2 inhibitors, already approved for diabetes, could soon disrupt Novartis's Entresto plans in CHF • Source: Shutterstock

The demonstration of reduced heart failure, death and other cardiovascular benefits with major classes of diabetes drugs means cardiovascular products like Novartis AG's congestive heart failure therapy Entresto must deal with imminent – and unexpected – competition from marketed metabolic drugs broadening their reach.

See Related Story

For more on Entresto's performance over time: (Also see "Novartis's Entresto Voyage: Hindsight Is 20/20" - Scrip, 15 May, 2017.)

Entresto (valsartan/sacubitril) has finally started to make its mark on the CHF market, but there are other products moving up...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Cardiovascular

More from Therapeutic Category